Veeva Systems Inc. (A1W5SA) Stock Price, News, Filings & Events

Veeva Systems Inc. is a leading provider of industry cloud solutions specifically designed for the global life sciences industry. The company offers a range of software, data, and consulting services that help life sciences companies manage their operations more efficiently and comply with regulatory requirements. Veeva's solutions cover various aspects of the life sciences industry, including clinical, regulatory, quality, and commercial operations. Veeva's customers include some of the world's largest pharmaceutical companies, as well as smaller biotech and medical device firms. These companies pay Veeva for its cloud-based software solutions, which help them streamline processes, ensure compliance, and bring medicines to market faster. Veeva's business model is primarily subscription-based, with customers paying recurring fees for access to its software platforms and services. The core business model of Veeva revolves around delivering specialized cloud solutions that integrate seamlessly into the life sciences workflow. By focusing on industry-specific needs and leveraging advanced technologies like AI, Veeva provides its clients with tools that enhance productivity, reduce costs, and improve decision-making across their operations.

Here are the top three recent material news items for Veeva Systems Inc. (VEE.GETTEX) from the last 90 days: 1. Veeva Introduces New EHS Application for Proactive Risk Management and Intelligent Automation (June 25, 2026) - Veeva launched Veeva EHS, a new application in its Quality Cloud for environmental, health, and safety. This solution aims to deliver real-time insights and streamline workflows, helping manufacturing and testing sites manage operational and environmental risks. This matters for shareholders as it expands Veeva's product offerings and enhances its value proposition in the life sciences industry, potentially driving revenue growth. 2. Veeva Acquires Copli, Launches Veeva Falcon MLR to Accelerate Content Review (June 23, 2026) - Veeva acquired Copli and introduced Veeva Falcon MLR, an agentic MLR solution that reduces manual effort in content review by up to 70%. This acquisition and product launch are significant as they enhance Veeva's capabilities in automating regulatory processes, which can lead to increased efficiency and cost savings for clients, potentially attracting more business. 3. Veeva Announces Fiscal 2027 First Quarter Results (June 3, 2026) - Veeva reported total revenues of $882.9 million, up 16% year over year, with subscription revenues of $730.2 million, up 15% year over year. This financial performance is crucial for shareholders as it demonstrates Veeva's strong growth trajectory and successful execution of its business strategy, which can positively impact investor confidence and stock valuation. These developments highlight Veev...

Veeva Systems Inc. (NYSE: VEEV) has demonstrated strong financial performance and strategic advancements, making a compelling bull case: - Consistent Revenue Growth : In fiscal year 2026, Veeva reported total revenues of $3.195 billion, a 16% increase from the previous year, with subscription services revenues rising 17% to $2.684 billion. (prnewswire.com) - Robust Profitability : The company achieved a net income of $908.91 million in fiscal year 2026, reflecting a 27.27% year-over-year growth, and maintained a strong profit margin of 28.44%. (stockanalysis.com) - Strategic Collaborations : Veeva's partnership with Amgen aims to enhance clinical trial innovation, potentially accelerating the development of new medicines and strengthening its position in the life sciences sector. (ir.veeva.com) - Expanding Customer Base : Over 450 companies, including 19 of the top 20 biopharmas, have adopted Veeva's Regulatory Information Management (RIM) platform, indicating widespread industry trust and adoption. (ir.veeva.com) - Innovative Product Development : The introduction of Veeva AI reflects the company's commitment to integrating advanced technologies, positioning it to meet evolving industry needs and drive future growth. (prnewswire.com) These factors collectively highlight Veeva's strong market position and potential for sustained growth.

Veeva Systems Inc. (VEE.GETTEX) faces several significant risks that could impact its future performance: - CRM Platform Migration Challenges : Veeva is transitioning its CRM application from Salesforce to its proprietary Vault platform, a complex process expected to complete between 2026 and 2029. This migration carries execution risks, including potential customer disruption and technical complexities, as clients must manage custom code and integrations themselves. (trefis.com) - Intensifying Competition : Following Veeva's separation from Salesforce in September 2025, Salesforce has entered the life sciences cloud market with its own Life Sciences Cloud, securing over 40 customers, including a major global pharmaceutical company that previously used Veeva. This increased competition could erode Veeva's market share. (trefis.com) - Economic Sensitivity : Veeva's revenue is closely tied to the R&D budgets of pharmaceutical clients. An economic downturn or reduced drug pricing could lead to decreased R&D spending, negatively affecting Veeva's growth prospects. (dcfmodeling.com) - Industry Concentration Risk : Veeva's exclusive focus on the life sciences sector makes it vulnerable to industry-specific downturns. A sustained contraction in pharmaceutical R&D spending or industry consolidation could shrink its addressable market. (companygraph.me) - High Stock-Based Compensation : In fiscal year 2026, Veeva's stock-based compensation expense was 14.8% of revenue, significantly above the 10% threshold. This level of compensation could pressure margins and lead to shareholder...

Veeva Systems Inc. (ticker: VEE.GETTEX, ISIN: US9224751084) has several upcoming events in the next 6-12 months that could influence its stock performance. Upcoming Earnings Releases: - Fiscal Q2 2027 Results: Expected on September 2, 2026, based on past reporting schedules. (marketbeat.com) - Fiscal Q3 2027 Results: Likely in early December 2026, following the company's typical quarterly reporting pattern. Product Launches: - Veeva AI: Planned for release in December 2025, this AI integration aims to enhance Veeva's cloud software offerings for the life sciences industry. (ir.veeva.com) Regulatory Decisions: - No specific regulatory decisions affecting Veeva Systems are publicly known at this time. Other Notable Events: - Annual Meeting of Shareholders: Scheduled for June 17, 2026, at 9:00 AM PT. (ir.veeva.com) These events may impact Veeva's stock performance, and investors should monitor them closely.

In Veeva Systems Inc.'s most recent earnings call for Q1 Fiscal Year 2027, held on June 3, 2026, management emphasized several key areas: - Financial Performance : The company reported revenue of $882.95 million, a 16.32% year-over-year increase, and earnings per share (EPS) of $2.24, surpassing expectations by $0.10. (seekingalpha.com) - Product Innovation : Management highlighted the successful integration of the Ostro acquisition and the launch of the Falcon AI platform, underscoring their commitment to innovation in AI, Customer Relationship Management (CRM), and Crossix analytics. (stockanalysis.com) - Conservative Guidance : Despite strong performance, the company provided conservative guidance, citing the early-stage scaling of key R&D products. (stockanalysis.com) The overall tone of the call was cautiously optimistic, reflecting confidence in the company's strategic direction while acknowledging the challenges associated with scaling new products. Management did not specifically address certain topics, such as detailed timelines for the scaling of R&D products or potential risks associated with the integration of new acquisitions. For a more in-depth understanding, you can watch the full earnings call here: Veeva Systems Inc. Q3 2026 Earnings Call